Penobscot Investment Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.6M | Sell |
13,160
-836
| -6% | -$401K | 0.45% | 57 |
|
|
2026
Q1 | $6.88M | Buy |
13,996
+357
| +3% | +$194K | 0.54% | 43 |
|
|
2025
Q4 | $7.9M | Sell |
13,639
-223
| -2% | -$126K | 0.6% | 40 |
|
|
2025
Q3 | $6.72M | Sell |
13,862
-68
| -0.5% | -$31.7K | 0.52% | 42 |
|
|
2025
Q2 | $5.65M | Sell |
13,930
-3,674
| -21% | -$1.54M | 0.48% | 50 |
|
|
2025
Q1 | $8.76M | Sell |
17,604
-59
| -0.3% | -$32K | 0.82% | 33 |
|
|
2024
Q4 | $9.19M | Sell |
17,663
-1,431
| -7% | -$787K | 0.83% | 28 |
|
|
2024
Q3 | $11.8M | Sell |
19,094
-518
| -3% | -$307K | 1.06% | 24 |
|
|
2024
Q2 | $10.8M | Buy |
19,612
+2,246
| +13% | +$1.29M | 1.05% | 25 |
|
|
2024
Q1 | $10.1M | Sell |
17,366
-459
| -3% | -$258K | 1.07% | 25 |
|
|
2023
Q4 | $9.46M | Buy |
17,825
+130
| +0.7% | +$62.9K | 1.11% | 25 |
|
|
2023
Q3 | $8.96M | Buy |
17,695
+3,624
| +26% | +$1.93M | 1.22% | 24 |
|
|
2023
Q2 | $7.34M | Sell |
14,071
-405
| -3% | -$219K | 1.21% | 26 |
|
|
2023
Q1 | $8.34M | Buy |
14,476
+318
| +2% | +$179K | 1.45% | 23 |
|
|
2022
Q4 | $7.8M | Buy |
14,158
+87
| +0.6% | +$46.1K | 1.37% | 23 |
|
|
2022
Q3 | $7.14M | Buy |
14,071
+55
| +0.4% | +$30.8K | 1.33% | 25 |
|
|
2022
Q2 | $7.61M | Sell |
14,016
-145
| -1% | -$79.8K | 1.31% | 25 |
|
|
2022
Q1 | $8.36M | Buy |
14,161
+262
| +2% | +$151K | 1.22% | 25 |
|
|
2021
Q4 | $9.27M | Buy |
13,899
+192
| +1% | +$120K | 1.25% | 26 |
|
|
2021
Q3 | $7.83M | Buy |
13,707
+160
| +1% | +$87.8K | 1.16% | 27 |
|
|
2021
Q2 | $6.83M | Buy |
13,547
+420
| +3% | +$198K | 1.01% | 32 |
|
|
2021
Q1 | $5.99M | Buy |
13,127
+1,250
| +11% | +$597K | 0.95% | 33 |
|
|
2020
Q4 | $5.53M | Buy |
11,877
+1,780
| +18% | +$835K | 0.93% | 35 |
|
|
2020
Q3 | $4.46M | Buy |
10,097
+792
| +9% | +$327K | 0.84% | 40 |
|
|
2020
Q2 | $3.37M | Buy |
9,305
+1,255
| +16% | +$421K | 0.69% | 45 |
|
|
2020
Q1 | $2.28M | Buy |
8,050
+290
| +4% | +$91.4K | 0.54% | 54 |
|
|
2019
Q4 | $2.52M | Buy |
7,760
+210
| +3% | +$63.7K | 0.47% | 64 |
|
|
2019
Q3 | $2.2M | Buy |
7,550
+1,080
| +17% | +$309K | 0.44% | 71 |
|
|
2019
Q2 | $1.9M | Buy |
6,470
+2,236
| +53% | +$616K | 0.39% | 74 |
|
|
2019
Q1 | $1.16M | Buy |
4,234
+1,080
| +34% | +$269K | 0.25% | 96 |
|
|
2018
Q4 | $706K | Hold |
3,154
| – | – | 0.17% | 117 |
|
|
2018
Q3 | $770K | Hold |
3,154
| – | – | 0.17% | 121 |
|
|
2018
Q2 | $653K | Hold |
3,154
| – | – | 0.15% | 132 |
|
|
2018
Q1 | $651K | Buy |
3,154
+1,720
| +120% | +$361K | 0.16% | 132 |
|
|
2017
Q4 | $272K | Hold |
1,434
| – | – | 0.08% | 168 |
|
|
2017
Q3 | $271K | Hold |
1,434
| – | – | 0.08% | 161 |
|
|
2017
Q2 | $250K | Buy |
+1,434
| New | +$241K | 0.08% | 167 |
|
Other funds holding TMO
Penobscot Investment Management's TMO Position: Q2 2026 in Review
Penobscot Investment Management reduced its Thermo Fisher Scientific (TMO) stake by 6% in Q2 2026, selling an estimated $401K and leaving 13,160 shares worth $6.6M. The position accounts for 0.45% of the portfolio, ranked #57.
Penobscot Investment Management first reported a position in TMO in Q2 2017 and has held it in 37 quarters since. The position peaked at $11.8M in Q3 2024. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Penobscot Investment Management held 13,160 shares of Thermo Fisher Scientific worth $6.6M as of Q2 2026.
- Penobscot Investment Management sold 836 Thermo Fisher Scientific shares in Q2 2026, an estimated $401K.
- Thermo Fisher Scientific made up 0.45% of Penobscot Investment Management's portfolio in Q2 2026, its #57 holding.
- Penobscot Investment Management first reported a position in Thermo Fisher Scientific in Q2 2017 and has held it in 37 quarters since.
- Penobscot Investment Management's Thermo Fisher Scientific position peaked at $11.8M in Q3 2024.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Penobscot Investment Management's 13F filing for Q2 2026, filed 24 Jul 2026.